CIBC Asset Management Inc Has $412,000 Stake in ICU Medical, Inc. (NASDAQ:ICUI)

CIBC Asset Management Inc lifted its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 9.8% during the third quarter, Holdings Channel.com reports. The firm owned 2,262 shares of the medical instruments supplier’s stock after buying an additional 201 shares during the quarter. CIBC Asset Management Inc’s holdings in ICU Medical were worth $412,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Victory Capital Management Inc. lifted its holdings in shares of ICU Medical by 0.5% during the 3rd quarter. Victory Capital Management Inc. now owns 142,535 shares of the medical instruments supplier’s stock worth $25,973,000 after acquiring an additional 687 shares during the period. GSA Capital Partners LLP raised its position in ICU Medical by 199.4% during the third quarter. GSA Capital Partners LLP now owns 7,808 shares of the medical instruments supplier’s stock valued at $1,423,000 after purchasing an additional 5,200 shares in the last quarter. WCM Investment Management LLC lifted its stake in ICU Medical by 1.3% during the third quarter. WCM Investment Management LLC now owns 259,481 shares of the medical instruments supplier’s stock worth $45,272,000 after purchasing an additional 3,407 shares during the last quarter. Versor Investments LP boosted its holdings in shares of ICU Medical by 210.0% in the 3rd quarter. Versor Investments LP now owns 7,118 shares of the medical instruments supplier’s stock valued at $1,297,000 after purchasing an additional 4,822 shares in the last quarter. Finally, Venturi Wealth Management LLC boosted its holdings in shares of ICU Medical by 1,510.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 302 shares in the last quarter. 96.10% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $163.46, for a total value of $1,961,520.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $17,096,771.78. This trade represents a 10.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction on Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the transaction, the vice president now owns 13,107 shares of the company’s stock, valued at approximately $2,139,324.54. This trade represents a 16.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,502 shares of company stock worth $6,573,496. Insiders own 6.70% of the company’s stock.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $168.84 on Friday. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The stock’s fifty day simple moving average is $176.43 and its two-hundred day simple moving average is $144.63. ICU Medical, Inc. has a 1-year low of $83.09 and a 1-year high of $196.26. The stock has a market cap of $4.13 billion, a PE ratio of -36.95 and a beta of 0.66.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Raymond James raised their price objective on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research note on Wednesday, November 13th. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday. Jefferies Financial Group assumed coverage on shares of ICU Medical in a research note on Monday, October 14th. They issued a “hold” rating and a $183.00 price objective for the company. Finally, KeyCorp boosted their target price on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 13th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.00.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.